The role of divalproex in the treatment of bipolar disorder

Psychiatric Annals

Volumn 32, Issue 12, 2002, Pages 742-750

  Bowden, Charles L ^a   Lawson, Diane M ^b   Cunningham, Muriel ^b   Owen, James Randall ^b   Tracy, Katherine A ^b,c  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b ABBOTT LABORATORIES   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; AMMONIA; ASPARTATE AMINOTRANSFERASE; CARBAMAZEPINE; CHOLESTEROL; ETHINYLESTRADIOL; HALOPERIDOL; LAMOTRIGINE; LEVONORGESTREL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OLANZAPINE; PLACEBO; SELENIUM; VALPROATE SEMISODIUM; ZINC;

ADD ON THERAPY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMMONIA BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BIPOLAR DISORDER; BLEEDING TENDENCY; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; DISEASE ASSOCIATION; DROWSINESS; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG WITHDRAWAL; EDEMA; GASTROINTESTINAL TOXICITY; HAIR LOSS; HEADACHE; HUMAN; HYPERAMMONEMIA; JAUNDICE; LETHARGY; LIVER TOXICITY; LOADING TEST; MAINTENANCE THERAPY; MANIC PSYCHOSIS; NAUSEA; PANCREATITIS; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REVIEW; RHINITIS; RISK FACTOR; SIDE EFFECT; SLURRED SPEECH; SOMNOLENCE; THROMBOCYTOPENIA; VITAMIN SUPPLEMENTATION; VOMITING; WEIGHT GAIN;

EID: 0036913455     PISSN: 00485713     EISSN: None     Source Type: Journal    
DOI: 10.3928/0048-5713-20021201-09     Document Type: Review

References (71)

1. Pope HG, McElroy SL, Keck PE Jr, Hudson JI. Valproate in the treatment of acute mania: a placebo-controlled study. Arch Gen Psychiatry. 1991;48:62-68.
2. Bowden CL, Brugger AM, Swann AC, et al. Efficacy of divalproex vs. lithium and placebo in the treatment of mania. JAMA. 1994;27:918-924.
3. Vasudev K, Goswami U, Kohli K. Carbamazepine and valproate monotherapy: feasibility, relative safety and efficacy, and therapeutic drug monitoring in manic disorder. Psychopharmacology. 2000;150:15-23.
4. Zajecka JM, Weisler R, Sachs G, Swann AC, Wozniak P, Sommerville KW. A comparison of the efficacy, safety and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry. In press.
5. Tohen M, Baker RW, Altshuler LL, et al. Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry. 2002;159:1011-1017.
6. Reviki DA, Paramore LC, Sommerville KW, Swann AC, Zajecka JM. Divalproex sodium versus olanzapine in the treatment of bipolar disorder: health-related quality of life and medical cost outcomes. J Clin Psychiatry. In press.
7. Solomon DA, Ryan CE, Keitner GI, et al. A pilot study of lithium carbonate plus divalproex sodium for the continuation and maintenance treatment of patients with bipolar I disorder. J Clin Psychiatry. 1997;58:95-99.
8. Muller-Oerlinghausen B, Retzow A, Henn FA, Giedke H, Walden J. Valproate as an adjunct to neuroleptic medication for the treatment of acute episodes of mania: a prospective, randomized, double-blind, placebo-controlled, multicenter study. J Clin Psychopharmacol. 2000;20:195-203.
9. Sachs GS, Grossman F, Ghaemi SN, Okamoto A, Bowden CL. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am J Psychiatry. 2002;159:1146-1154.
10. Bowden CL, Calabrese JR, McElroy SL et al. A randomized placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Arch Gen Psychiatry. 2000;57:481-489.
11. Dunner DL, Fieve RR. Clinical factors in lithium carbonate prophylaxis failure. Arch Gen Psychiatry. 1974;30:229-233.
12. Kukopulos A, Reginaldi D, Laddomada P, Floris G, Serra G, Tondo L. Course of the manic-depressive cycle and changes caused by treatment. Pharmakopsychiatrie, Neruo-Psychopharmakologie. 1980;13:156-167.
13. Calabrese JR, Markovitz PJ, Kimmel SE, Wagner SC. Spectrum of efficacy of valproate in 78 rapid cycling bipolar patients. J Clin Psychopharmacol. 1992;12(suppl 1):53S-56S.
14. Swann C, Bowden CL, Morris D, et al. Depression during mania: treatment response to lithium or divalproex. Arch Gen Psychiatry. 1997;54:37-42.
15. Winsberg, ME, DeGolia SG, Strong CM, Ketter TA. Divalproex therapy in medication-naive and mood-stabilizer-naive bipolar II depression. J Affect Disord. 2001;67:207-212.
16. Hayes SG. Long-term use of valproate in primary psychiatric disorders. J Clin Psychiatry. 1989;50:35-39.
17. Davis LL, Kabel D, Patel D, et al. Valproate as an antidepressant in major depressive disorder. Psychopharmacol Bull. 1996;32:647-652.
18. Gyulai L, Bowden CL, Calabrese JR, et al. Efficacy of divalproex for bipolar depression. Abstract presented at: American Psychiatric Association Annual Meeting; May 13-18, 2000; Chicago, Ill. Abstract NR464.
19. McElroy SL, Keck PE Jr, Stanton SP, Tugrul KC, Bennett JA, Strakowski SM. A randomized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania. J Clin Psychiatry. 1996;57:142-146.
20. Wassef AA, Hafiz NG, Hampton D, Molloy M. Divalproex sodium augmentation of haloperidol in hospitalized patients with schizophrenia: clinical and economic implications. J Clin Psychopharmacol. 2001;21:21-26.
21. Casey DE, Daniel DG, Wassef AA, Tracy KA, Wozniak P, Sommerville KW, for the Depakote Psychosis Group. Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbations of schizophrenia. Neuropsychopharmacology. In press. Available at: http://www.acnp.org/citations/ Npp060702324. Accessed June 7, 2002.
22. Wagner KD, Weller E, Carlson G, et al. An open-label trial of divalproex in children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry. In press.
23. Kowatch RA, Suppes T, Carmody TJ, et al. Effect size of lithium, divalproex sodium, and carbamazepine in children and adolescents with bipolar disorder. J Am Acad Adolesc Psychiatry. 2000;39:713-720.
24. Donovan SJ, Stewart JW, Nunes EV, et al. Divalproex treatment for youth with explosive temper and mood lability: a double-blind, placebo-controlled crossover design. Am J Psychiatry. 2000;157:818-820.
25. Hollander E, Swann A, Coccaro EF et al. Divalproex sodium is superior to placebo for impulsive aggression in cluster B personality disorders. Poster presented at: American Psychiatric Association Annual Meeting; May 18-23, 2002; Philadelphia, Pa.
26. Porteinsson AP, Tariot PN, Erb R et al. Placebo-controlled study of divalproex sodium for agitation in dementia. Am J Geriatr Psychiatry. 2001;9:58-66.
27. Tariot PN, Schneider LS, Mintzer JE, et al. Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: results of a double-blind, placebo-controlled trial. Current Therapeutic Research. 2001;62(1):51-67.
28. Brown R. U.S. Experience with valproate in manic depressive illness: a multicenter trial. J Clin Psychiatry. 1989;50:3(suppl)13-16.
29. Frankenburg FR, Zanarini MC. Divalproex sodium treatment of women with borderline personality disorder and comorbid bipolar II disorder: a double-blind placebo-controlled pilot study. J Clin Psychiatry. 2002;63:442-446.
30. Hollander E, Allen A, Prieto-Lopez R, et al. A preliminary double blind, placebo-controlled trial of divalproex sodium in borderline personality disorder. J Clin Psychiatry. 2001;62:199-203.
31. Reoux JP, Saxon AJ, Malte CA, Baer JS, Sloan KL. Divalproex sodium in alcohol withdrawal: a randomized double-blind placebo-controlled clinical trial. Alcohol Clin Exp Res. 2001;25:1324-1329.
32. McElroy SL, Keck PE Jr, Lawrence JM. Treatment of panic disorder and benzodiazepine withdrawal with valproate. J Neuropsychiatry Clin Neurosci. 1991;3:232-233.
33. Depakote® Tablets Product Information, 2001. Divalproex Sodium Delayed-Release Tablets, Abbott Laboratories, Abbott Park, IL.
34. Depakote® ER Product Information, 2001. Divalproex Sodium Extended-Release Tablets, Abbott Laboratories, Abbott Park, IL.
35. Dutta S, Zhang Y, Selness DS, Lee LL, Williams LA, Sommerville KW. Comparison of the bioavailability of unequal doses of divalproex sodium extended-release formulation relative to the delayed-release formulation in healthy volunteers. Epilepsy Res. 2002;49:1-10.
36. Bowden CL, Janicak PG, Orsulak PJ et al. Relation of serum valproate concentration to response in mania. Am J Psychiatry. 1996;153:765-770.
37. Keck PE Jr, McElroy SL, Tugrul KC, Bennett JA. Valproate oral loading in the treatment of acute mania. J Clin Psychiatry. 1993;54:305-308.
38. Hirschfeld RMA, Allen MH, McEvoy JP, Keck PE Jr, Russel JM. Safety and tolerability of oral loading divalproex sodium in acutely manic bipolar patients. J Clin Psychiatry. 1999;60:815-818.
39. Martinez JM, Russell JM, Hirschfeld RMA. Tolerability of oral loading of divalproex sodium in the treatment of acute mania. Depress Anxiety. 1998;7:83-86.
40. Carraz G, Gau R, Chateau R, et al. Communication a propos des premiers essays cliniques sur l'actvite anti-epilpetique de l'acide n-dipropylacetique (sel de Na+) Ann Med Psychol. 1964;122:577-585.
41. Laljee HCK, Parsonnage MJ. Unwanted effects of sodium valproate in the treatment of adult patients with epilepsy. In: Parsonnage M, Caldwell ADS, eds. The Place of Sodium Valproate in the Treatment of Epilepsy. London: Royal Society of Medicine and Academic Press; 1980:141-158.
42. McElroy SL, Keck PE Jr. Treatment guidelines for valproate in bipolar and schizoaffective disorders. Can J Psychiatry. 1993;38(suppl 2):S62-S66.
43. Carney P, Nasreddine W, Drury I, et al. Relationship between thrombocytopenia and valproate dose. Epilepsia. 1997;38(suppl 8):102.
44. Cole AP. Transient thrombocytopenia in a child on sodium valproate. Dev Med Child Neurol. 1978;20:487-490.
45. Guyton AC, ed. Textbook of Medical Physiology. 8th ed. Philadelphia, Pa: WB Saunders Company; 1991;390-399.
46. Willmore LJ, Wilder BJ, Bruni J, Villarreal HJ. Effect of valproic acid on hepatic function. Neurology. 1978;28:961-964.
47. Dreifuss FE, Santilli N, Langer DH et al. Valproic acid fatalities: a retrospective review. Neurology. 1987;37:379-385.
48. Dreifuss FE, Langer DH, Moline KA, Maxwell JE. Valproic acid hepatic fatalities II: US experience since 1984. Neurology. 1989;39:201-207.
49. Bryant AE, Dreifuss FE. Valproic acid hepatic fatalities III. US experience since 1986. Neurology. 1996;46:465-469.
50. Asconape JJ, Penry JK, Dreifuss FE, Riela A, Mirza W. Valproate-associated pancreatitis. Epilepsia. 1993;34:177-183.
51. Pellock JM, Wilder BJ, Deaton R, Sommerville KW. Acute pancreatitis coincident with valproate use: a critical review. Epilepsia. In press.
52. Honeycutt D, Callahan K, Rutledge L, Evans B. Heterozygote ornithine transcarbamylase deficiency presenting as symptomatic hyperammonemia during initiation of valproate therapy. Neurology. 1992;42:666-668.
53. Oechsner M, Steen C, Sturenburg HJ, Kohlschutter A. Hyperammonaemic encephalopathy after initiation of valproate therapy in unrecognised ornithine transcarbamylase deficiency. J Neurol Neurosurg Psychiatry. 1998;64:680-682.
54. Kulick SK, Kramer DA. Hyperammonemia secondary to valproic acid as a cause of lethargy in a postictal patient. Ann Emerg Med. 1993;22:610-612.
55. Zaccara G, Paganini M, Campostrini R, Arnetoli G, Zappoli R, Moroni F. Hyperammonemia and valproate-induced alterations of the state of consciousness. Eur Neurol. 1984;23:104-112.
56. Ernst CL, Goldberg JF. The reproductive safety profile of mood stabilizers, atypical antipsychotics, and broad-spectrum psychotropics. J Clin Psychiatry. 2002;63(suppl 4):42-55.
57. Rasgon NL, Altshuler LL, Gudeman D, et al. Medication status and polycystic ovary syndrome in women with bipolar disorder: a preliminary report. J Clin Psychiatry. 2000;61:173-178.
58. Center for Disease Control and Prevention. Valproic acid and spina bifida: a preliminary report-France. Morb Mortal Wkly Rep. 1982;31:565-566.
59. Centers for Disease Control and Prevention. Valproate: a new cause of birth defects - report from Italy and follow-up from France. MMWR Morb Mortal Wkly Rep. 1983;32:438-439.
60. Centers for Disease Control and Prevention. Periconceptional use of multivitamins and the occurrence of anencephaly and spina bifida. MMRW Morb Mortal Wkly Rep. 1988;37:727-730.
61. Milunsky A, Jick H, Jick SS, et al. Multivitamin/folic acid supplementation in early pregnancy reduces the prevalence of neural tube defects. JAMA. 1989;262:2847-2852.
62. Kennedy D, Koren G. Valproic acid use in psychiatry: issues in treating women of reproductive age. J Psychiatry Neurosci. 1998;23:223-228.
63. Davis R, Peters DH, McTavish D. Valproic acid, a reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs. 1994;47:332-372.
64. Abbott FS, Kassam J Orr JM, Farrell K. The effect of aspirin on valproic acid metabolism. Clin Pharmacol Ther. 1986;40:94-100.
65. Wong SL, Cavanaugh J, Shi H, Awni WA, Granneman R. Effects of divalproex sodium on amitryptyline and nortriptyline pharmacokinetics. Clin Pharmacol Ther. 1996;60:48-53.
66. Panjehshahin MR, Bowmen CJ, Yates MS. Effect of valproic acid, its unsaturated metabolites and same structurally related fatty acids on the binding of warfarin and dansylsacrosine to human albumin. Biochem Pharmacol. 1991;41:1227-1233.
67. Yuen AWC, Land G, Weatherly BC, Peck AW. Sodium valproate acutely inhibits lamotrigine metabolism. Br J Clin Pharmacol. 1992;33:511-513.
68. Li LM, Russo M, O'Donoghue MF, Duncan JS, Sander JWAS. Allergic Skin rash with lamotrigine and concomitant valproate therapy. Arq Neuropsiquiatr. 1996;54:47-49.
69. Crawford P, Chadwick D, Cleland P et al. The lack of effect of sodium valproate on the pharmacokinetics of oral contraceptive steroids. Contraception. 1986;33:23-29.
70. Manji HK, Moore GJ, Chen G. Clinical and preclinical evidence for the neurotrophic effects of mood stabilizers: implications for the pathophysiology and treatment of manic-depressive illness. Biol Psychiatry. 2000;48:740-754.
71. Gottlicher M, Minucci S, Zhu P, et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 2001;29:6969-6978.